The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation
The DOI matches its Crossref record.
Abstract
Benzodiazepine discontinuation is characterized by a syndrome of increased activity and reduced seizure threshold that is similar to effects mediated by the glutamatergic system. To elucidate the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation, we administered lorazepam, the NMDA antagonist CPP, and the combination of these compounds either concomitantly or consecutively to mice via osmotic pumps and evaluated pentylenetetrazole-induced seizure threshold, open-field activity, and benzodiazepine receptor binding during and after chronic administration. Animals receiving lorazepam alone developed partial tolerance at 7 days and complete tolerance at 14 days to the anticonvulsant effects of lorazepam. This effect was partly attenuated by CPP coadministration with lorazepam. This combination produced only partial tolerance. A reduction in seizure threshold was observed 4 days after discontinuation of lorazepam alone. This effect was abolished by coadministration of CPP with lorazepam and by CPP administration during the withdrawal period. Benzodiazepine binding in most structures examined was significantly reduced at 14 days during chronic lorazepam administration (versus 1 day), and coadministration of CPP did not alter this decrement. After lorazepam discontinuation, binding was increased at 4 and 7 days versus chronically treated animals and versus vehicle within the cerebral cortex. This effect was abolished by coadministration of CPP as well as by CPP administration during the lorazepam withdrawal period. These data support the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, lorazepam-induced tolerance to its acute anticonvulsant effects was partially prevented with simultaneous CPP treatment [122].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [122]
Citations
Cites
Still being checked.
Cited by
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
“Also, lorazepam-induced tolerance to its acute anticonvulsant effects was partially prevented with simultaneous CPP treatment [122].”
BackgroundNeuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160
Low-dose subcutaneous ketamine infusion and morphine tolerance
Bell, R. F. (1999) · Pain · doi:10.1016/s0304-3959(99)00096-2 · Cited by 98
Izzo, E., Auta, J., Impagnatiello, F., Pesold, C., Guidotti, A., & Costa, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628698 · Cited by 90
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 95
Metadata
- Authors
- Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G.
- Affiliations
- Tufts University (US)
- ORCID
- Greenblatt, David J.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2008-06-10
- Volume
- 55
- Issue
- 5
- Pages
- 217-227
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2017337653
- Cited by
- 33
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2013: 1 · 2012: 2
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01mh047598-03)
- National Institute of Mental Health (MH 34223, MH-47598)
- National Institute on Drug Abuse (DA05258)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- benzodiazepine tolerance, benzodiazepine discontinuation, NMDA receptor antagonists, CPP, lorazepam, glutamatergic system, seizure threshold, benzodiazepine binding, benzodiazepine withdrawal, pentylenetetrazole-induced seizures, cerebral cortex
- MeSH terms
- Animals, Cerebral Cortex, Drug Interactions, Drug Tolerance, Hippocampus, Lorazepam, Male, Motor Activity, Pentylenetetrazole, Piperazines, Receptors, GABA-A, Seizures, Substance Withdrawal Syndrome, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. https://app.cochat.ai/papers/10.1159/000139531
- The paper
- Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G. (2008). The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. Pharmacology. https://doi.org/10.1159/000139531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.